Targeting nicotinic receptors for Parkinson's disease therapy

CNS and Neurological Disorders - Drug Targets

Volumn 10, Issue 6, 2011, Pages 651-658

  Quik, Maryka ^a   Bordia, Tanuja ^a   Huang, Luping ^a   Perez, Xiomara ^a  

^a SRI INTERNATIONAL   (United States)

Author keywords

Dyskinesias; Levodopa; Neuroprotection; Nicotine; Nicotinic receptors; Parkinson's disease; Parkinsonian

Indexed keywords

BUNGAROTOXIN RECEPTOR; DOPAMINE; LEVODOPA; LIPOPOLYSACCHARIDE; MECAMYLAMINE; NICOTINE; NICOTINE PATCH; NICOTINIC RECEPTOR;

ALZHEIMER DISEASE; ARTICLE; BRAIN DAMAGE; COGNITION; DISEASE ASSOCIATION; DOPAMINE RELEASE; DOPAMINERGIC SYSTEM; DYSKINESIA; HUMAN; NERVE DEGENERATION; NEUROMODULATION; NEUROPROTECTION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; SMOKING; SYNAPTIC TRANSMISSION;

EID: 80052841371     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/187152711797247849     Document Type: Article

References (143)

1. Schapira, A.H.; Emre, M.; Jenner, P.; Poewe, W. Levodopa in the treatment of Parkinson's disease. Eur. J. Neurol., 2009, 16, 982-989
2. Fahn, S. How do you treat motor complications in Parkinson's disease: Medicine, surgery, or both? Ann. Neurol., 2009, 64(S2), S56-S64
3. Stocchi, F.; Tagliati, M.; Olanow, C.W. Treatment of levodopa-induced motor complications. Mov. Disord., 2008, 23(Suppl 3), S599-S612
4. Kieburtz, K. Therapeutic strategies to prevent motor complications in Parkinson's disease. J. Neurol., 2008, 255(Suppl 4), 42-45
5. Kieburtz, K. Therapeutic strategies to prevent motor complications in Parkinson's disease. J. Neurol., 2008, 255(Suppl 4), 42-45
6. Fox, S.H.; Lang, A.E. Levodopa-related motor complications-phenomenology. Mov. Disord., 2008, 23(Suppl 3), S509-S514
7. Fox, S.H.; Chuang, R.; Brotchie, J.M. Parkinson's disease-opportunities for novel therapeutics to reduce the problems of levodopa therapy. Prog. Brain Res. 2008, 172, 479-494
8. Quik, M.; Cox, H.; Parameswaran, N.; O'Leary, K.; Langston, J.W.; Di Monte, D. Nicotine reduces levodopa-induced dyskinesias in lesioned monkeys. Ann. Neurol., 2007, 62, 588-596
9. Bordia, T.; Campos, C.; Huang, L.; Quik, M. Continuous and intermittent nicotine treatment reduces L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesias in a rat model of Parkinson's disease. J. Pharmacol. Exp. Therap., 2008, 327, 239-247
10. Huang, L.Z.; Bordia, T.; Quik, M. Nicotine treatment reduces L-dopa-induced dyskinetic-like movements in parkinsonian mice. Soc. Neurosci. Abst., 2009, on line
11. Quik, M.; O'Leary, K.; Tanner, C.M. Nicotine and Parkinson's disease: implications for therapy. Mov. Disord., 2008, 23, 1641-1652
12. Picciotto, M.R.; Addy, N.A.; Mineur, Y.S.; Brunzell, D.H. It is not "either/or": Activation and desensitization of nicotinic acetylcholine receptors both contribute to behaviors related to nicotine addiction and mood. Prog. Neurobiol., 2008, 84, 329-342
13. O'Neill, M.J.; Murray, T.K.; Lakics, V.; Visanji, N.P.; Duty, S. The role of neuronal nicotinic acetylcholine receptors in acute and chronic neurodegeneration. CNS Neurol. Disord. Drug Targets, 2002, 1, 399-411
14. Elbaz, A.; Moisan, F. Update in the epidemiology of Parkinson's disease. Curr. Opin. Neurol., 2008, 21, 454-460
15. Ritz, B.; Ascherio, A.; Checkoway, H.; Marder, K.S.; Nelson, L.M.; Rocca, W.A.; Ross, G.W.; Strickland, D.; Van Den Eeden, S.K.; Gorell, J. Pooled analysis of tobacco use and risk of Parkinson disease. Arch. Neurol., 2007, 64, 990-7
16. Thacker, E.L.; O'Reilly, E.J.; Weisskopf, M.G.; Chen, H.; Schwarzschild, M.A.; McCullough, M.L.; Calle, E.E.; Thun, M.J.; Ascherio, A. Temporal relationship between cigarette smoking and risk of Parkinson disease. Neurology, 2007, 68, 764-768
17. Allam, M.F.; Campbell, M.J.; Hofman, A.; Del Castillo, A.S.; Fernandez-Crehuet Navajas, R. Smoking and Parkinson's disease: systematic review of prospective studies. Mov. Disord., 2004, 19, 614-621
18. Zhou, F.M.; Liang, Y.; Dani, J.A. Endogenous nicotinic cholinergic activity regulates dopamine release in the striatum. Nat. Neurosci., 2001, 4, 1224-1229
19. Zhou, F.M.; Wilson, C.; Dani, J.A. Muscarinic and nicotinic cholinergic mechanisms in the mesostriatal dopamine systems. Neuroscientist, 2003, 9, 23-36
20. Fuxe, K.; Hoekfelt, T.; Nilsson, O. Observations on the Cellular Localization of Dopamine in the Caudate Nucleus of the Rat. Z. Zellforsch. Mikrosk. Anat., 1964, 63, 701-706
21. Fonnum, F. Recent developments in biochemical investigations of cholinergic transmission. Brain Res., 1973, 62, 497-507
22. Gotti, C.; Clementi, F.; Fornari, A.; Gaimarri, A.; Guiducci, S.; Manfredi, I.; Moretti, M.; Pedrazzi, P.; Pucci, L.; Zoli, M. Structural and functional diversity of native brain neuronal nicotinic receptors. Biochem. Pharmacol., 2009, 78, 703-711
23. Albuquerque, E.X.; Pereira, E.F.; Alkondon, M.; Rogers, S.W. Mammalian nicotinic acetylcholine receptors: from structure to function. Physiol. Rev., 2009, 89, 73-120
24. Millar, N.S.; Gotti, C. Diversity of vertebrate nicotinic acetylcholine receptors. Neuropharmacology, 2009, 56, 237-246
25. Zoli, M.; Moretti, M.; Zanardi, A.; McIntosh, J.M.; Clementi, F.; Gotti, C. Identification of the nicotinic receptor subtypes expressed on dopaminergic terminals in the rat striatum. J. Neurosci., 2002, 22, 8785-8789
26. Champtiaux, N.; Gotti, C.; Cordero-Erausquin, M.; David, D.J.; Przybylski, C.; Lena, C.; Clementi, F.; Moretti, M.; Rossi, F.M.; Le Novere, N.; McIntosh, J.M.; Gardier, A.M.; Changeux, J.P. Subunit composition of functional nicotinic receptors in dopaminergic neurons investigated with knock-out mice. J. Neurosci., 2003, 23, 7820-7829
27. Salminen, O.; Murphy, K.L.; McIntosh, J.M.; Drago, J.; Marks, M.J.; Collins, A.C.; Grady, S.R. Subunit composition and pharmacology of two classes of striatal presynaptic nicotinic acetylcholine receptors mediating dopamine release in mice. Mol. Pharmacol., 2004, 65, 1526-1535
28. Quik, M.; Vailati, S.; Bordia, T.; Kulak, J.M.; Fan, H.; McIntosh, J.M.; Clementi, F.; Gotti, C. Subunit composition of nicotinic receptors in monkey striatum: effect of treatments with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine or L-DOPA. Mol. Pharmacol., 2005, 67, 32-41
29. Benowitz, N.L. Pharmacology of nicotine: addiction, smoking- induced disease, and therapeutics. Ann. Rev. Pharmacol. Toxicol., 2009, 49, 57-71
30. Grady, S.R.; Salminen, O.; Laverty, D.C.; Whiteaker, P.; McIntosh, J.M.; Collins, A.C.; Marks, M.J. The subtypes of nicotinic acetylcholine receptors on dopaminergic terminals of mouse striatum. Biochem. Pharmacol., 2007, 74(8), 1235-1246
31. Exley, R.; Cragg, S.J. Presynaptic nicotinic receptors: a dynamic and diverse cholinergic filter of striatal dopamine neurotransmission. Br. J. Pharmacol., 2008, 153(Suppl 1), S283-S297
32. Calabresi, P.; Di Filippo, M. ACh/dopamine crosstalk in motor control and reward: a crucial role for alpha 6-containing nicotinic receptors? Neuron, 2008, 60, 4-7
33. Nelson, M.E.; Kuryatov, A.; Choi, C.H.; Zhou, Y.; Lindstrom, J. Alternate stoichiometries of alpha4beta2 nicotinic acetylcholine receptors. Mol. Pharmacol., 2003, 63, 332-341
34. Grady, S.R.; Salminen, O.; McIntosh, J.M.; Marks, M.J.; Collins, A.C. Mouse Striatal Dopamine Nerve Terminals Express alpha4alpha5beta2 and Two Stoichiometric Forms of alpha4beta2*-Nicotinic Acetylcholine Receptors. J. Mol. Neurosci., 2009, 40, 91-95
35. Moroni, M.; Zwart, R.; Sher, E.; Cassels, B.K.; Bermudez, I. alpha4beta2 nicotinic receptors with high and low acetylcholine sensitivity: pharmacology, stoichiometry, and sensitivity to longterm exposure to nicotine. Mol. Pharmacol., 2006, 70(2), 755-768
36. Lester, H.A.; Xiao, C.; Srinivasan, R.; Son, C.D.; Miwa, J.; Pantoja, R.; Banghart, M.R.; Dougherty, D.A.; Goate, A.M.; Wang, J.C. Nicotine is a selective pharmacological chaperone of acetylcholine receptor number and stoichiometry. Implications for drug discovery. AAPS J., 2009, 11, 167-177
37. Drenan, R.M.; Grady, S.R.; Whiteaker, P.; McClure-Begley, T.; McKinney, S.; Miwa, J.M.; Bupp, S.; Heintz, N.; McIntosh, J.M.; Bencherif, M.; Marks, M.J.; Lester, H.A. In vivo activation of midbrain dopamine neurons via sensitized, high-affinity alpha 6 nicotinic acetylcholine receptors. Neuron, 2008, 60, 123-136
38. Pons, S.; Fattore, L.; Cossu, G.; Tolu, S.; Porcu, E.; McIntosh, J.M.; Changeux, J.P.; Maskos, U.; Fratta, W. Crucial role of alpha4 and alpha6 nicotinic acetylcholine receptor subunits from ventral tegmental area in systemic nicotine self-administration. J. Neurosci., 2008, 28, 12318-12327
39. Jones, I.W.; Bolam, J.P.; Wonnacott, S. Presynaptic localisation of the nicotinic acetylcholine receptor beta2 subunit immunoreactivity in rat nigrostriatal dopaminergic neurones. J. Comp. Neurol., 2001, 439, 235-247
40. Bordia, T.; Grady, S.R.; McIntosh, J.M.; Quik, M. Nigrostriatal damage preferentially decreases a subpopulation of alpha6beta2* nAChRs in mouse, monkey, and Parkinson's disease striatum. Mol. Pharmacol., 2007, 72, 52-61
41. Champtiaux, N.; Han, Z.Y.; Bessis, A.; Rossi, F.M.; Zoli, M.; Marubio, L.; McIntosh, J.M.; Changeux, J.P. Distribution and pharmacology of alpha 6-containing nicotinic acetylcholine receptors analyzed with mutant mice. J. Neurosci., 2002, 22, 1208-1217
42. Quik, M.; Bordia, T.; Forno, L.; McIntosh, J.M. Loss of alpha- conotoxinMII- and A85380-sensitive nicotinic receptors in Parkinson's disease striatum. J. Neurochem., 2004, 88, 668-679
43. Dajas-Bailador, F.; Wonnacott, S. Nicotinic acetylcholine receptors and the regulation of neuronal signalling. Trends Pharmacol. Sci., 2004, 25, 317-324
44. Livingstone, P.D.; Wonnacott, S. Nicotinic acetylcholine receptors and the ascending dopamine pathways. Biochem. Pharmacol., 2009, 78, 744-755
45. Marchi, M.; Risso, F.; Viola, C.; Cavazzani, P.; Raiteri, M. Direct evidence that release-stimulating alpha7* nicotinic cholinergic receptors are localized on human and rat brain glutamatergic axon terminals. J. Neurochem., 2002, 80, 1071-1078
46. Wooltorton, J.R.; Pidoplichko, V.I.; Broide, R.S.; Dani, J.A. Differential desensitization and distribution of nicotinic acetylcholine receptor subtypes in midbrain dopamine areas. J. Neurosci., 2003, 23, 3176-3185
47. Azam, L.; McIntosh, J.M. Alpha-conotoxins as pharmacological probes of nicotinic acetylcholine receptors. Acta Pharmacol. Sin., 2009, 30, 771-783.
48. Kulak, J.M.; Nguyen, T.A.; Olivera, B.M.; McIntosh, J.M. Alpha- conotoxin MII blocks nicotine-stimulated dopamine release in rat striatal synaptosomes. J. Neurosci., 1997, 17, 5263-5270
49. Exley, R.; Clements, M.A.; Hartung, H.; McIntosh, J.M.; Cragg, S.J. Alpha6-containing nicotinic acetylcholine receptors dominate the nicotine control of dopamine neurotransmission in nucleus accumbens. Neuropsychopharmacology, 2008, 33, 2158-2166
50. Meyer, E.L.; Yoshikami, D.; McIntosh, J.M. The neuronal nicotinic acetylcholine receptors alpha 4* and alpha 6* differentially modulate dopamine release in mouse striatal slices. J. Neurochem., 2008, 105, 1761-1769
51. Perez, X.A.; O'Leary, K.T.; Parameswaran, N.; McIntosh, J.M.; Quik, M. Prominent role of alpha3/alpha6beta2* nAChRs in regulating evoked dopamine release in primate putamen: effect of long-term nicotine treatment. Mol. Pharmacol., 2009, 75, 938-946
52. Perez, X.A.; Parameswaran, N.; Huang, L.Z.; O'Leary, K.T.; Quik, M. Pre-synaptic dopaminergic compensation after moderate nigrostriatal damage in non-human primates. J. Neurochem., 2008, 105, 1861-1872
53. Rice, M.E.; Cragg, S.J. Nicotine amplifies reward-related dopamine signals in striatum. Nat. Neurosci., 2004, 7, 583-584
54. Zhang, L.; Zhou, F.M.; Dani, J.A. Cholinergic drugs for Alzheimer's disease enhance in vitro dopamine release. Mol. Pharmacol., 2004, 66, 538-544
55. Zhang, T.; Zhang, L.; Liang, Y.; Siapas, A.G.; Zhou, F.M.; Dani, J.A. Dopamine signaling differences in the nucleus accumbens and dorsal striatum exploited by nicotine. J. Neurosci., 2009, 29, 4035-4043
56. Zhang, X.; Zhou, Z.; Wang, D.; Li, A.; Yin, Y.; Gu, X.; Ding, F.; Zhen, X.; Zhou, J. Activation of phosphatidylinositol-linked D1-like receptor modulates FGF-2 expression in astrocytes via IP3- dependent Ca2+ signaling. J. Neurosci., 2009, 29, 7766-7775
57. Perez, X.A.; Bordia, T.; McIntosh, J.M.; Grady, S.R.; Quik, M. Long-term nicotine treatment differentially regulates striatal alpha6alpha4beta2* and alpha6(nonalpha4)beta2* nAChR expression and function. Mol. Pharmacol., 2008, 74, 844-853
58. Brazell, M.P.; Mitchell, S.N.; Joseph, M.H.; Gray, J.A. Acute administration of nicotine increases the in vivo extracellular levels of dopamine, 3,4-dihydroxyphenylacetic acid and ascorbic acid preferentially in the nucleus accumbens of the rat: comparison with caudate-putamen. Neuropharmacology, 1990, 29, 1177-1185
59. Domino, E.F.; Tsukada, H. Nicotine sensitization of monkey striatal dopamine release. Eur. J. Pharmacol., 2009, 607, 91-95
60. Imperato, A.; Mulas, A.; Di Chiara, G. Nicotine preferentially stimulates dopamine release in the limbic system of freely moving rats. Eur. J. Pharmacol., 1986, 132, 337-338
61. Lecca, D.; Shim, I.; Costa, E.; Javaid, J.I. Striatal application of nicotine, but not of lobeline, attenuates dopamine release in freely moving rats. Neuropharmacology, 2000, 39, 88-98
62. Marshall, D.L.; Redfern, P.H.; Wonnacott, S. Presynaptic nicotinic modulation of dopamine release in the three ascending pathways studied by in vivo microdialysis: comparison of naive and chronic nicotine-treated rats. J. Neurochem., 1997, 68, 1511-1519
63. Toth, E.; Sershen, H.; Hashim, A.; Vizi, E.S.; Lajtha, A. Effect of nicotine on extracellular levels of neurotransmitters assessed by microdialysis in various brain regions: role of glutamic acid. Neurochem. Res., 1992, 17, 265-271
64. Marubio, L.M.; Gardier, A.M.; Durier, S.; David, D.; Klink, R.; Arroyo-Jimenez, M.M.; McIntosh, J.M.; Rossi, F.; Champtiaux, N.; Zoli, M.; Changeux, J.P. Effects of nicotine in the dopaminergic system of mice lacking the alpha4 subunit of neuronal nicotinic acetylcholine receptors. Eur. J. Neurosci., 2003, 17, 1329-1337
65. Picciotto, M.R.; Zoli, M.; Rimondini, R.; Lena, C.; Marubio, L.M.; Pich, E.M.; Fuxe, K.; Changeux, J.P. Acetylcholine receptors containing the beta2 subunit are involved in the reinforcing properties of nicotine. Nature, 1998, 391, 173-177
66. Quik, M.; Huang, L.Z.; Parameswaran, N.; Bordia, T.; Campos, C.; Perez, X.A. Multiple roles for nicotine in Parkinson's disease. Biochem. Pharmacol., 2009, 78, 677-685
67. Aubert, I.; Araujo, D.M.; Cecyre, D.; Robitaille, Y.; Gauthier, S.; Quirion, R. Comparative alterations of nicotinic and muscarinic binding sites in Alzheimer's and Parkinson's diseases. J. Neurochem., 1992, 58, 529-541
68. Court, J.A.; Piggott, M.A.; Lloyd, S.; Cookson, N.; Ballard, C.G.; McKeith, I.G.; Perry, R.H.; Perry, E.K. Nicotine binding in human striatum: elevation in schizophrenia and reductions in dementia with Lewy bodies, Parkinson's disease and Alzheimer's disease and in relation to neuroleptic medication. Neuroscience, 2000, 98, 79-87
69. Perry, E.K.; Morris, C.M.; Court, J.A.; Cheng, A.; Fairbairn, A.F.; McKeith, I.G.; Irving, D.; Brown, A.; Perry, R.H. Alteration in nicotine binding sites in Parkinson's disease, Lewy body dementia and Alzheimer's disease: possible index of early neuropathology. Neuroscience, 1995, 64, 385-395
70. Rinne, J.O.; Myllykyla, T.; Lonnberg, P.; Marjamaki, P. A postmortem study of brain nicotinic receptors in Parkinson's and Alzheimer's disease. Brain Res., 1991, 547, 167-170
71. Bohr, I.J.; Ray, M.A.; McIntosh, J.M.; Chalon, S.; Guilloteau, D.; McKeith, I.G.; Perry, R.H.; Clementi, F.; Perry, E.K.; Court, J.A.; Piggott, M.A. Cholinergic nicotinic receptor involvement in movement disorders associated with Lewy body diseases. An autoradiography study using [(125)I] alpha-conotoxinMII in the striatum and thalamus. Exp. Neurol., 2005, 191, 292-300
72. Gotti, C.; Moretti, M.; Bohr, I.; Ziabreva, I.; Vailati, S.; Longhi, R.; Riganti, L.; Gaimarri, A.; McKeith, I.G.; Perry, R.H.; Aarsland, D.; Larsen, J.P.; Sher, E.; Beattie, R.; Clementi, F.; Court, J.A. Selective nicotinic acetylcholine receptor subunit deficits identified in Alzheimer's disease, Parkinson's disease and dementia with Lewy bodies by immunoprecipitation. Neurobiol. Dis., 2006, 23, 481-489
73. Quik, M.; Sum, J.D.; Whiteaker, P.; McCallum, S.E.; Marks, M.J.; Musachio, J.; McIntosh, J.M.; Collins, A.C.; Grady, S.R. Differential declines in striatal nicotinic receptor subtype function after nigrostriatal damage in mice. Mol. Pharmacol., 2003, 63, 1169-1179
74. McCallum, S.E.; Parameswaran, N.; Bordia, T.; Fan, H.; McIntosh, J.M.; Quik, M. Differential regulation of mesolimbic alpha 3/alpha 6 beta 2 and alpha 4 beta 2 nicotinic acetylcholine receptor sites and function after long-term oral nicotine to monkeys. J. Pharmacol. Exp. Therap., 2006, 318, 381-388
75. McCallum, S.E.; Parameswaran, N.; Bordia, T.; McIntosh, J.M.; Grady, S.R.; Quik, M. Decrease in alpha3*/alpha6* nicotinic receptors but not nicotine-evoked dopamine release in monkey brain after nigrostriatal damage. Mol. Pharmacol., 2005, 68, 737-746
76. McCallum, S.E.; Parameswaran, N.; Bordia, T.; Fan, H.; Tyndale, R.F.; Langston, J.W.; McIntosh, J.M.; Quik, M. Increases in alpha4* but not alpha3*/alpha6* nicotinic receptor sites and function in the primate striatum following chronic oral nicotine treatment. J. Neurochem., 2006, 96, 1028-1041
77. Marks, M.J.; Burch, J.B.; Collins, A.C. Effects of chronic nicotine infusion on tolerance development and nicotinic receptors. J. Pharmacol. Exp. Ther., 1983, 226, 817-825
78. Schwartz, R.D.; Kellar, K.J. Nicotinic cholinergic receptor binding sites in the brain: regulation in vivo. Science, 1983, 220, 214-216
79. Benwell, M.E.; Balfour, D.J.; Anderson, J.M. Evidence that tobacco smoking increases the density of (-)-[3H]nicotine binding sites in human brain. J. Neurochem., 1988, 50, 1243-1247
80. Perry, D.C.; Davila-Garcia, M.I.; Stockmeier, C.A.; Kellar, K.J. Increased nicotinic receptors in brains from smokers: membrane binding and autoradiography studies. J. Pharmacol. Exp. Ther., 1999, 289, 1545-1552
81. Rahman, S.; Zhang, J.; Corrigall, W.A. Effects of acute and chronic nicotine on somatodendritic dopamine release of the rat ventral tegmental area: in vivo microdialysis study. Neurosci. Lett., 2003, 348, 61-64
82. Visanji, N.P.; Mitchell, S.N.; O'Neill, M.J.; Duty, S. Chronic pretreatment with nicotine enhances nicotine-evoked striatal dopamine release and alpha6 and beta3 nicotinic acetylcholine receptor subunit mRNA in the substantia nigra pars compacta of the rat. Neuropharmacology, 2006, 50, 36-46
83. Yu, Z.J.; Wecker, L. Chronic nicotine administration differentially affects neurotransmitter release from rat striatal slices. J. Neurochem., 1994, 63(1), 186-194
84. Grady, S.R.; Grun, E.U.; Marks, M.J.; Collins, A.C. Pharmacological comparison of transient and persistent [3H] dopamine release from mouse striatal synaptosomes and response to chronic L-nicotine treatment. J. Pharmacol. Exp. Ther., 1997, 282, 32-43
85. Grilli, M.; Parodi, M.; Raiteri, M.; Marchi, M. Chronic nicotine differentially affects the function of nicotinic receptor subtypes regulating neurotransmitter release. J. Neurochem., 2005, 93, 1353-1360
86. Jacobs, I.; Anderson, D.J.; Surowy, C.S.; Puttfarcken, P.S. Differential regulation of nicotinic receptor-mediated neurotransmitter release following chronic (-)-nicotine administration. Neuropharmacology, 2002, 43, 847-856
87. Lai, A.; Parameswaran, N.; Khwaja, M.; Whiteaker, P.; Lindstrom, J.M.; Fan, H.; McIntosh, J.M.; Grady, S.R.; Quik, M. Long-term nicotine treatment decreases striatal alpha 6* nicotinic acetylcholine receptor sites and function in mice. Mol. Pharmacol., 2005, 67, 1639-1647
88. Marks, M.J.; Grady, S.R.; Collins, A.C. Downregulation of nicotinic receptor function after chronic nicotine infusion. J. Pharmacol. Exp. Ther., 1993, 266, 1268-1276
89. Lang, A.E. When and how should treatment be started in Parkinson disease? Neurology, 2009, 72(7 Suppl), S39-S43
90. Ahlskog, J.E.; Muenter, M.D. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov. Disord., 2001, 16, 448-458
91. Thanvi, B.; Lo, N.; Robinson, T. Levodopa-induced dyskinesia in Parkinson's disease: clinical features, pathogenesis, prevention and treatment. Postgrad. Med. J., 2007, 83, 384-388
92. Fabbrini, G.; Brotchie, J.M.; Grandas, F.; Nomoto, M.; Goetz, C.G. Levodopa-induced dyskinesias. Mov. Disord., 2007, 22, 1379-1389
93. Brotchie, J.M.; Lee, J.; Venderova, K. Levodopa-induced dyskinesia in Parkinson's disease. J. Neural Transm., 2005, 112, 359-391
94. Cenci, M.A.; Lundblad, M. Postversus presynaptic plasticity in L-DOPA-induced dyskinesia. J. Neurochem., 2006, 99, 381-392
95. Cenci, M.A.; Lundblad, M. Ratings of L-DOPA-induced dyskinesia in the unilateral 6-OHDA lesion model of Parkinson's disease in rats and mice. Curr. Prot. Neurosci. 2007, Chapter 9, Unit 925
96. Guigoni, C.; Aubert, I.; Li, Q.; Gurevich, V.V.; Benovic, J.L.; Ferry, S.; Mach, U.; Stark, H.; Leriche, L.; Hakansson, K.; Bioulac, B.H.; Gross, C.E.; Sokoloff, P.; Fisone, G.; Gurevich, E.V.; Bloch, B.; Bezard, E. Pathogenesis of levodopa-induced dyskinesia: focus on D1 and D3 dopamine receptors. Parkinsonism Relat. Disord. 2005, 11(Suppl 1), S25-S29
97. Guigoni, C.; Li, Q.; Aubert, I.; Dovero, S.; Bioulac, B.H.; Bloch, B.; Crossman, A.R.; Gross, C.E.; Bezard, E. Involvement of sensorimotor, limbic, and associative basal ganglia domains in L-3,4-dihydroxyphenylalanine-induced dyskinesia. J. Neurosci., 2005, 25, 2102-2107
98. Linazasoro, G. New ideas on the origin of L-dopa-induced dyskinesias: age, genes and neural plasticity. Trends Pharmacol. Sci., 2005, 26, 391-397
99. Mercuri, N.B.; Bernardi, G. The 'magic' of L-dopa: why is it the gold standard Parkinson's disease therapy? Trends Pharmacol. Sci., 2005, 26, 341-344
100. Samadi, P.; Bedard, P.J.; Rouillard, C. Opioids and motor complications in Parkinson's disease. Trends Pharmacol. Sci., 2006, 27, 512-517
101. Linazasoro, G.; Van Blercom, N.; Ugedo, L.; Ruiz Ortega, J.A. Pharmacological treatment of Parkinson's disease: life beyond dopamine D2/D3 receptors? J. Neural Trans., 2008, 115, 431-441
102. Carta, M.; Carlsson, T.; Munoz, A.; Kirik, D.; Bjorklund, A. Serotonin-dopamine interaction in the induction and maintenance of L-DOPA-induced dyskinesias. Prog. Brain Res., 2008, 172, 465-478
103. Bordia, T.; Campos, C.; McIntosh, J.M.; Quik, M. Nicotinic receptor-mediated reduction in L-dopa-induced dyskinesias may occur via desensitization. J. Pharmacol. Exp. Ther., 2010, 333, 929-938
104. Gotti, C.; Moretti, M.; Gaimarri, A.; Zanardi, A.; Clementi, F.; Zoli, M. Heterogeneity and complexity of native brain nicotinic receptors. Biochem. Pharmacol., 2007, 74, 1102-1111
105. Quik, M.; Bordia, T.; O'Leary, K. Nicotinic receptors as CNS targets for Parkinson's disease. Biochem. Pharmacol., 2007, 74, 1224-1234
106. Huang, L.Z.; Campos, C.; Ly, J.; Carroll, F.I.; Quik, M. Nicotinic receptor agonists decrease L-dopa-induced dyskinesias most effectively in moderately lesioned parkinsonian rats. Neuropharmacology, 2011, 60, 861-868
107. Ishikawa, A.; Miyatake, T. Effects of smoking in patients with early-onset Parkinson's disease. J. Neurol. Sci., 1993, 117, 28-32
108. Fagerstrom, K.O.; Pomerleau, O.; Giordani, B.; Stelson, F. Nicotine may relieve symptoms of Parkinson's disease. Psychopharmacology, 1994, 116, 117-119.
109. Clemens, P.; Baron, J.A.; Coffey, D.; Reeves, A. The short-term effect of nicotine chewing gum in patients with Parkinson's disease. Psychopharmacology, 1995, 117, 253-256
110. Ebersbach, G.; Stock, M.; Muller, J.; Wenning, G.; Wissel, J.; Poewe, W. Worsening of motor performance in patients with Parkinson's disease following transdermal nicotine administration. Mov. Disord., 1999, 14, 1011-1013
111. Kelton, M.C.; Kahn, H.J.; Conrath, C.L.; Newhouse, P.A. The effects of nicotine on Parkinson's disease. Brain Cog., 2000, 43, 274-282
112. Vieregge, A.; Sieberer, M.; Jacobs, H.; Hagenah, J.M.; Vieregge, P. Transdermal nicotine in PD: a randomized, double-blind, placebocontrolled study. Neurology, 2001, 57, 1032-1035
113. Villafane, G.; Cesaro, P.; Rialland, A.; Baloul, S.; Azimi, S.; Bourdet, C.; Le Houezec, J.; Macquin-Mavier, I.; Maison, P. Chronic high dose transdermal nicotine in Parkinson's disease: an open trial. Eur. J. Neurol., 2007, 14, 1313-1316
114. Shoulson, I. Randomized placebo-controlled study of the nicotinic agonist SIB-508Y in Parkinson disease. Neurology, 2006, 66, 408-410
115. Lemay, S.; Chouinard, S.; Blanchet, P.; Masson, H.; Soland, V.; Beuter, A.; Bedard, M.A. Lack of efficacy of a nicotine transdermal treatment on motor and cognitive deficits in Parkinson's disease. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2004, 28(1), 31-39
116. Hancock, D.B.; Martin, E.R.; Mayhew, G.M.; Stajich, J.M.; Jewett, R.; Stacy, M.A.; Scott, B.L.; Vance, J.M.; Scott, W.K. Pesticide exposure and risk of Parkinson's disease: a family-based case- control study. BMC Neurol., 2008, 8, 6
117. Costa, G.; Abin-Carriquiry, J.A.; Dajas, F. Nicotine prevents striatal dopamine loss produced by 6-hydroxydopamine lesion in the substantia nigra. Brain Res., 2001, 888, 336-342
118. Huang, L.Z.; Parameswaran, N.; Bordia, T.; Michael McIntosh, J.; Quik, M. Nicotine is neuroprotective when administered before but not after nigrostriatal damage in rats and monkeys. J. Neurochem., 2009, 109, 826-837
119. Jeyarasasingam, G.; Tompkins, L.; Quik, M. Stimulation of non-alpha7 nicotinic receptors partially protects dopaminergic neurons from 1-methyl-4-phenylpyridinium-induced toxicity in culture. Neuroscience, 2002, 109, 275-285
120. Park, H.J.; Lee, P.H.; Ahn, Y.W.; Choi, Y.J.; Lee, G.; Lee, D.Y.; Chung, E.S.; Jin, B.K. Neuroprotective effect of nicotine on dopaminergic neurons by anti-inflammatory action. Eur. J. Neurosci., 2007, 26, 79-89
121. Quik, M.; O'Neill, M.; Perez, X.A. Nicotine neuroprotection against nigrostriatal damage: importance of the animal model. Trends Pharmacol. Sci., 2007, 28, 229-235
122. Quik, M.; Parameswaran, N.; McCallum, S.E.; Bordia, T.; Bao, S.; McCormack, A.; Kim, A.; Tyndale, R.F.; Langston, J.W.; Di Monte, D.A. Chronic oral nicotine treatment protects against striatal degeneration in MPTP-treated primates. J. Neurochem., 2006, 98, 1866-1875
123. Picciotto, M.R.; Zoli, M. Neuroprotection via nAChRs: the role of nAChRs in neurodegenerative disorders such as Alzheimer's and Parkinson's disease. Front. Biosci., 2008, 13, 492-504
124. Bazzu, G.; Calia, G.; Puggioni, G.; Spissu, Y.; Rocchitta, G.; Debetto, P.; Grigoletto, J.; Zusso, M.; Migheli, R.; Serra, P.A.; Desole, M.S.; Miele, E. alpha-Synuclein- and MPTP-generated rodent models of Parkinson's disease and the study of extracellular striatal dopamine dynamics: a microdialysis approach. CNS Neurol. Disord. Drug Targets, 2010, 9, 482-490
125. Chesselet, M.F. In vivo alpha-synuclein overexpression in rodents: a useful model of Parkinson's disease? Exp. Neurol., 2008, 209(1), 22-27
126. Ulusoy, A.; Decressac, M.; Kirik, D.; Bjorklund, A. Viral vectormediated overexpression of alpha-synuclein as a progressive model of Parkinson's disease. Prog. Brain Res., 2010, 184, 89-111
127. Mandel, S.A.; Fishman-Jacob, T.; Youdim, M.B. Modeling sporadic Parkinson's disease by silencing the ubiquitin E3 ligase component, SKP1A. Parkinsonism Relat. Disord., 2009, 15(Suppl 3), S148-S151
128. Alves, G.; Kurz, M.; Lie, S.A.; Larsen, J.P. Cigarette smoking in Parkinson's disease: influence on disease progression. Mov. Disord., 2004, 19(9), 1087-1092
129. Khwaja, M.; McCormack, A.; McIntosh, J.M.; Di Monte, D.A.; Quik, M. Nicotine partially protects against paraquat-induced nigrostriatal damage in mice; link to alpha6beta2* nAChRs. J. Neurochem., 2007, 100, 180-190
130. Ryan, R.E.; Ross, S.A.; Drago, J.; Loiacono, R.E. Dose-related neuroprotective effects of chronic nicotine in 6-hydroxydopamine treated rats, and loss of neuroprotection in alpha4 nicotinic receptor subunit knockout mice. Br. J. Pharmacol., 2001, 132, 1650-1656
131. Marrero, M.B.; Bencherif, M. Convergence of alpha 7 nicotinic acetylcholine receptor-activated pathways for anti-apoptosis and anti-inflammation: central role for JAK2 activation of STAT3 and NF-kappaB. Brain Res., 2009, 1256, 1-7
132. Takeuchi, H.; Yanagida, T.; Inden, M.; Takata, K.; Kitamura, Y.; Yamakawa, K.; Sawada, H.; Izumi, Y.; Yamamoto, N.; Kihara, T.; Uemura, K.; Inoue, H.; Taniguchi, T.; Akaike, A.; Takahashi, R.; Shimohama, S. Nicotinic receptor stimulation protects nigral dopaminergic neurons in rotenone-induced Parkinson's disease models. J. Neurosci. Res., 2009, 87, 576-585
133. Ren, K.; Puig, V.; Papke, R.L.; Itoh, Y.; Hughes, J.A.; Meyer, E.M. Multiple calcium channels and kinases mediate alpha7 nicotinic receptor neuroprotection in PC12 cells. J. Neurochem., 2005, 94, 926-933
134. Shen, J.X.; Yakel, J.L. Nicotinic acetylcholine receptor-mediated calcium signaling in the nervous system. Acta Pharmacol. Sin., 2009, 30, 673-680.
135. Quik, M. Smoking, nicotine and Parkinson's disease. Trends Neurosci., 2004, 27, 561-568
136. Liu, Q.; Zhao, B. Nicotine attenuates beta-amyloid peptide-induced neurotoxicity, free radical and calcium accumulation in hippocampal neuronal cultures. Br. J. Pharmacol., 2004, 141, 746-754
137. Zhao, J.; Xin, M.; Wang, T.; Zhang, Y.; Deng, X. Nicotine Enhances the Antiapoptotic Function of Mcl-1 through Phosphorylation. Mol. Cancer Res., 2009, 7, 1954-1961
138. von Bohlen und Halbach, O.; Unsicker, K. Neurotrophic support of midbrain dopaminergic neurons. Adv. Exp. Med. Biol., 2009, 651, 73-80.
139. Luchtman, D.W.; Shao, D.; Song, C. Behavior, neurotransmitters and inflammation in three regimens of the MPTP mouse model of Parkinson's disease. Physiol. Behav., 2009, 98, 130-138.
140. Stolp, H.B.; Dziegielewska, K.M. Review: Role of developmental inflammation and blood-brain barrier dysfunction in neurodevelopmental and neurodegenerative diseases. Neuropath. Appl. Neurobiol., 2009, 35, 132-146
141. Shi, F.D.; Piao, W.H.; Kuo, Y.P.; Campagnolo, D.I.; Vollmer, T.L.; Lukas, R.J. Nicotinic attenuation of central nervous system inflammation and autoimmunity. J. Immunol., 2009, 182, 1730-1739
142. Duron, E.; Hanon, O. Vascular risk factors, cognitive decline, and dementia. Vasc. Health Risk Manag., 2008, 4, 363-381
143. Sabbagh, M.N.; Lukas, R.J.; Sparks, D.L.; Reid, R.T. The nicotinic acetylcholine receptor, smoking, and Alzheimer's disease. J. Alzheimers Dis., 2002, 4, 317-325